Clinical trials: High Risk Cancer
Diffuse Large B-cell Lymphoma
Oral Panobinostat Adult Patients DLBCL Relapsed/Refractory Stem Cell Transfusion (ASCT) or Not Eligible for ASCT
Treatment of adult patients with Diffuse Large B-cell Lymphoma (DLBCL), relapsed or refractory to previous CHOP-R (or CHOP-R like regimen) front line therapy, relapsed or refractory to second or subsequent salvage therapies which…
- Trial name
- FIL_PanAL10 (NCT01523834)
- Testing
- Panobinostat
- Where
- 10 sites in Italy
- Volunteers
- 35 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Malignant Glioma, Glioblastoma Multiforme
Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma
The purpose of this study was to evaluate the safety and potential efficacy of CAN-2409 (also known / previously described as AdV-tk, GMCI) for malignant gliomas.
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High Grade Glioma
- Trial name
- BrTK02 (NCT00589875)
- Testing
- CAN-2409, Valacyclovir, Temozolomide
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- Candel Therapeutics, Inc.
Barretts Esophagus, Esophageal High-Grade Intraepithelial Neoplasia
Barrett&Apos;s Intervention for Dysplasia by Endoscopy
LAY SUMMARY A type of gullet cancer (oesophageal adenocarcinoma) has become the 5th commonest UK cause of cancer death. Unfortunately, by the time patients have symptoms, the cancer is often incurable.
- Conditions
- Barretts Esophagus, Esophageal High-Grade Intraepithelial Neoplasia, Esophageal Cancer Stage I
- Trial name
- BRIDE (NCT01733719)
- Testing
- ER plus RFA, ER plus APC
- Where
- 5 sites in United Kingdom
- Volunteers
- 76 people
- Sponsor
- University Hospitals, Leicester
Myeloma, Stem Cell Transplantation
Lenalidomide and High-Dose Melphalan
The goal of this clinical research study is to find the highest tolerable dose of the combination of Revlimid (lenalidomide) and high-dose Alkeran (melphalan) that can be given to patients with multiple myeloma who will receive…
- Trial name
- NCT01079936
- Testing
- Lenalidomide, Melphalan, Stem Cell Infusion
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- M.D. Anderson Cancer Center
Sarcoma
Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST
In this study, patients who have been diagnosed with gastrointestinal stromal tumor (GIST) and have been treated with adjuvant imatinib for 3 years after surgery will be randomly allocated in a 1:1 ratio to receive imatinib…
- Trial name
- NCT02413736
- Testing
- Imatinib
- Where
- Finland
- Volunteers
- 255 people
- Sponsor
- Heikki Joensuu
Transitional Cell Carcinoma
Weekly TP-HDFL in the Treatment of Advanced TCC
The purpose of this study is to evaluate the efficacy of Weekly TP-HDFL in advanced transitional cell carcinoma in terms of response rate and overall survival.
- Trial name
- NCT00154687
- Testing
- Paclitaxel, Cisplatin, 5-Fluorouracil
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
Colorectal Neoplasms
S0820, Adenoma and Second Primary Prevention Trial
The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0…
- Trial name
- PACES (NCT01349881)
- Testing
- Eflornithine plus sulindac
- Where
- 989 sites in United States
- Volunteers
- 354 people
- Sponsor
- SWOG Cancer Research Network
Childhood Acute Lymphoblastic Leukemia, Philadelphia Chromosome, Ph^1^, Absent
Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia
The cure rate for childhood acute lymphoblastic leukemia (ALL) has increased significantly in recent decades and expected cure rates now exceed 85%.
- Conditions
- Childhood Acute Lymphoblastic Leukemia, Philadelphia Chromosome, Ph^1^, Absent, B-cell Childhood Acute Lymphoblastic Leukemia
- Trial name
- NCT01990807
- Testing
- Idarubicin(IDA)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese Academy of Medical Sciences
Sarcoma
High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma
RATIONALE: Drugs used in chemotherapy, such as vincristine, irinotecan, ifosfamide, etoposide, doxorubicin, cyclophosphamide, and dactinomycin, work in different ways to stop the growth of tumor cells, either by killing the cells…
- Trial name
- NCT00354744
- Testing
- dactinomycin, cyclophosphamide, doxorubicin hydrochloride
- Where
- 166 sites in United States, Australia and 3 more
- Volunteers
- 109 people
- Sponsor
- Children's Oncology Group
Melanoma
Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma
The goal of this clinical trial is to study the impact of Neoadjuvant ipilimumab and nivolumab for melanoma patients that had recurrence during or after adjuvant anti-PD-1 therapy.
- Trial name
- NeoRelapse (NCT06365619)
- Testing
- Ipilimumab, Nivolumab
- Sponsor
- University of Utah
Lymphoma
Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma
This phase II clinical trial studies how well yttrium Y 90 ibritumomab tiuxetan, rituximab, and high-dose chemotherapy followed by peripheral blood stem cell transplant in treating patients with relapsed B-cell non-Hodgkin…
- Trial name
- NCT00695409
- Testing
- rituximab, carmustine, cytarabine
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- City of Hope Medical Center
Acute Myeloid Leukemia
Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission
The primary aim of this innovative immunotherapeutic study is to determine whether the antileukemic effects seen in our previous phase I/II study can be confirmed in a large cohort of patients and whether dendritic cell…
- Trial name
- WIDEA (NCT01686334)
- Testing
- DC vaccine
- Where
- 8 sites in Belgium
- Volunteers
- 130 people
- Sponsor
- Zwi Berneman
Multiple Myeloma
QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression
The primary objective is to evaluate when Revlimid and Dexamethasone treatment extend the time to progression to symptomatic MM in patients with smoldering MM.
- Trial name
- QUIREDEX (NCT00480363)
- Testing
- Maintenance with lower doses of lenalidomide and dexamethasone
- Where
- 13 sites in Spain
- Volunteers
- 120 people
- Sponsor
- PETHEMA Foundation
Hematopoietic Neoplasm
Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis
Primary Objective: To evaluate the efficacy of daily oral doses of 400 mg or 500 mg of SAR302503 (Investigational Medicinal Product, IMP) compared to placebo in the reduction of spleen volume as determined by magnetic resonance…
- Trial name
- JAKARTA (NCT01437787)
- Testing
- SAR302503
- Where
- 101 sites in United States, Australia and 23 more
- Volunteers
- 289 people
- Sponsor
- Bristol-Myers Squibb
Lung Neoplasms, Pancreatic Neoplasms
Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis Techniques
This is a combined prospective and retrospective observational study aiming to validate a highly sensitive and specific blood-based method for the early diagnosis and post-treatment monitoring of multiple cancers.
- Conditions
- Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Esophageal Neoplasms
- Trial name
- NCT07035587
- Testing
- Serial Blood Sampling for Molecular Profiling, One-Time Blood Sampling for Molecular Profiling
- Where
- South Korea
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Pancreatic Cancer
High-activity Natural Killer Immunotherapy for Small Metastases of Pancreatic Cancer
The aim of this study is the safety and efficacy of high-activity natural killer immunotherapy to small metastases of pancreatic cancer.
- Trial name
- NCT03008304
- Testing
- High-activity natural killer
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
High Grade Cervical Intra-epithelial Neoplasia
Colposcopy Versus HPV Testing to Identify Persistent Cervical Precancers
This trial will compare HPV testing to the routine colposcopy in the follow-up of women treated for cervical high grade lesions.
- Trial name
- CoHIPP (NCT01051895)
- Testing
- high risk HPV DNA testing, Active comparator: Routine colposcopy
- Where
- Canada
- Volunteers
- 2,253 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Prostate Cancer
Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer - Protocol 2
This study will explore the combination of a stereotactic body radiation therapy (SBRT) approach combined with one year of luteinizing hormone releasing hormone (LHRH) agonist for older men with high risk prostate cancer, or men…
- Trial name
- FASTR-2 (NCT02229734)
- Testing
- Radiation, Androgen Suppression
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Sarcoma
Pazopanib Maintenance Phase II
This trial compares pazopanib to placebo as maintenance treatment over 2 years in patients with retroperitoneal and visceral high-risk soft tissue sarcomas after multimodal treatment including prior neo- and/or adjuvant…
- Trial name
- NCT02207309
- Testing
- Pazopanib
- Where
- Germany
- Volunteers
- 1 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Myeloma
A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
This is a single-center, single arm, phase I study designed to determine the safety and find the recommended Phase 2 dose (RP2D) or maximum dose level (MTD) of Belantamab Mafodotin in patients with high-risk smoldering multiple…
- Trial name
- NCT05055063
- Testing
- Belantamab mafodotin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.